BBBruno Monteiro Barros

Bruno Monteiro Barros

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bruno Monteiro Barros has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Venetoclax Plus Rituximab for Relapse/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis of Treatments Available in Brazil

    by Bruno M. Barros, Márcia Gisele S. Costa, Marcelo G. Correia, Carlos S. Magliano, Pedro Vitor P. Lima, Natália B. Santoni, Andreas Duva, Maria Isabel Duran

    Introduction Venetoclax represents a significant advancement in target anticancer therapy in the management of relapsed/refractory chronic lymphocytic leukemia (RR-CLL). This study aims to compare the efficacy and safety of the venetoclax + rituximab (VenR) regimen with other therapies approved in Brazil. Methods A systematic review and network meta-analysis (NMA) was conducted to evaluate the efficacy and safety of treatments approved in Brazil for RR-CLL. Comprehensive literature searches were performed to identify randomized controlled trials. Risk of bias and certainty of evidence for each outcome were assessed across the included studies. The NMA was conducted using a frequentist framework. The primary efficacy outcomes were progression-free survival, overall survival, overall response rate, and time to next therapy. Safety was assessed on the basis of the incidence of serious adverse events. Results A total of 24 publications related to 12 trials were identified and included. VenR was associated with better survival outcomes when compared with standard regimens such as rituximab (HR 0.16; 95% CI 0.03–0.74) and physician choice (HR 0.17; 95% CI 0.04–0.81). In terms of progression-free survival, VenR achieved HR < 0.20, supported by narrow confidence intervals, when compared to treatments such as bendamustine plus rituximab, ofatumumab and physician choice, in addition to significantly favorable results compared to ibrutinib and acalabrutinib. Approximately half of the studies presented a low risk of bias, and the certainty of evidence assessed using the GRADE-NMA approach resulted in very low certainty of evidence, mainly due to risk of bias, intransitivity, and imprecision. Conclusion This NMA provides valuable evidence to support rational therapeutic choices for RR-CLL in Brazil, highlighting VenR and Bruton tyrosine kinase inhibitors as leading treatment options across diverse clinical scenarios.

  • Open Access

    Systematic Review of the Effectiveness of Intensive Antihypertensive Treatment Goals: Brazilian Society of Cardiology (SBC) Recommendation

    by Andréa Araujo Brandão, Cibele Isaac Saad Rodrigues, Luiz Aparecido Bortolotto, Leonardo Castro Luna, Bruno Monteiro Barros, Mario Fritsch Toros Neves, Ana Flávia de Souza Moura, Frida Liane Plavnik, Luciano Ferreira Drager, Osni Moreira Filho, et al.

    Background Strict blood pressure control has been investigated as a strategy to reduce severe cardiovascular events in patients with hypertension. However, there are still doubts about the impact of intensive antihypertensive treatment goals (< 130/80 mmHg) compared to conventional goals (≥ 130/80 mmHg) in preventing myocardial infarction, stroke, mortality, and possible treatment-related adverse effects. Objective To evaluate the effectiveness of intensive antihypertensive treatment goals in reducing critical cardiovascular events compared to usual goals. Methods This systematic review included randomized controlled trials (RCTs) that compared intensive blood pressure control goals with conventional goals in adults aged 18 years or older. Studies with at least one of the following outcomes were included: mortality, myocardial infarction, stroke, progression to stage 4 or 5 chronic kidney disease, need for dialysis, or kidney transplantation. Medline, Embase, and Cochrane Library databases were searched up to May 2024. Risk of bias assessment was performed by two independent reviewers using the Cochrane Collaboration’s Risk of Bias 2 (RoB 2) tool. Synthesis of results was conducted through meta-analysis for the composite outcome of myocardial infarction, stroke, and all-cause mortality. The certainty of scientific evidence and strength of recommendation followed the methods proposed by the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) tool. Results Nine RCTs with more than 34,000 participants were included. Intensive treatment was associated with a 13% reduction in cardiovascular events. In the studies with low risk of bias, the reduction was 17%, with high certainty of evidence. Separately, a significant reduction was observed in the outcomes of myocardial infarction and stroke, but not in all-cause mortality. Limited data were found on the progression of kidney disease and the need for dialysis or kidney transplantation. Conclusion High-quality evidence suggests that more intensive antihypertensive treatment goals significantly reduce cardiovascular events. However, the choice of treatment goals should be individualized, considering factors such as age, frailty, individual cardiovascular risk, and the possibility of adverse events. Adherence to treatment is essential to therapeutic success.


  • Open Access

    Revisão Sistemática sobre a Eficácia de Metas Intensivas do Tratamento Anti-Hipertensivo: Recomendação da Sociedade Brasileira de Cardiologia (SBC)

    by Andréa Araujo Brandão, Cibele Isaac Saad Rodrigues, Luiz Aparecido Bortolotto, Leonardo Castro Luna, Bruno Monteiro Barros, Mario Fritsch Toros Neves, Ana Flávia de Souza Moura, Frida Liane Plavnik, Luciano Ferreira Drager, Osni Moreira Filho, et al.

    Resumo Fundamento O controle rigoroso da pressão arterial tem sido investigado como uma estratégia para reduzir eventos cardiovasculares graves em pacientes hipertensos. No entanto, ainda existem dúvidas sobre o impacto de metas intensivas de tratamento anti-hipertensivo (meta < 130/80 mmHg) em comparação com metas convencionais (≥ 130/80 mmHg) na prevenção de infarto do miocárdio, acidente vascular cerebral, mortalidade e possíveis eventos adversos do tratamento. Objetivo Avaliar a eficácia de metas intensivas de tratamento anti-hipertensivo na redução de eventos cardiovasculares críticos em comparação com metas usuais. Métodos Esta revisão sistemática incluiu ensaios clínicos randomizados (ECRs) que compararam metas intensivas de controle da pressão arterial com metas convencionais em adultos com 18 anos ou mais. Foram incluídos estudos com pelo menos um dos seguintes desfechos: mortalidade, infarto do miocárdio, acidente vascular cerebral, progressão para doença renal crônica em estágios IV ou V, necessidade de diálise ou transplante renal. As bases de dados Medline, Embase e Cochrane Library foram pesquisadas até maio de 2024. A avaliação do risco de viés foi realizada por dois revisores independentes utilizando a ferramenta Risk of Bias 2 (RoB 2) da Colaboração Cochrane. A síntese dos resultados foi conduzida por meio de metanálise para o desfecho composto de infarto do miocárdio, acidente vascular cerebral e mortalidade por todas as causas. A certeza da evidência científica e a força de recomendação seguiram os métodos propostos pela ferramenta GRADE (Grading of Recommendations Assessment, Development and Evaluation). Resultados Foram incluídos nove ECRs com mais de 34.000 participantes. O tratamento intensivo foi associado a uma redução de 13% nos eventos cardiovasculares. Nos estudos com baixo risco de viés, a redução foi de 17%, com alta certeza da evidência. Separadamente, observou-se uma redução significativa nos desfechos de infarto do miocárdio e acidente vascular cerebral, mas não na mortalidade por todas as causas. Dados limitados foram encontrados sobre a progressão da doença renal e necessidade de diálise ou transplante renal. Conclusão As evidências de alta qualidade sugerem que metas mais intensivas de tratamento anti-hipertensivo reduzem significativamente os eventos cardiovasculares. Contudo, a escolha das metas de tratamento deve ser individualizada, considerando fatores como idade, fragilidade, o risco cardiovascular individual e a possibilidade de eventos adversos. A adesão ao tratamento é fundamental para o sucesso terapêutico.


  • Open Access

    Risk of Adverse Health Outcomes in Patients with Poor Adherence to Cardiovascular Medication Treatment: A Systematic Review

    by Marcus Vinícius Bolívar Malachias, Sergio Emanuel Kaiser, Denilson Campos de Albuquerque, Andrea Araújo Brandão, Andrei Carvalho Sposito, Lidia Zytysnky Moura, Lucélia Batista Neves Cunha Magalhães, Marco Antonio Mota-Gomes, Nadine Clausell, Paulo César Veiga Jardim, et al.

    Background Cardiovascular diseases (CVD) remain the leading cause of mortality worldwide. Medication adherence is an important issue in managing chronic CVD, directly influencing outcomes and healthcare costs. Objectives This systematic review, supported by the Brazilian Society of Cardiology, evaluates the impact of poor adherence to cardiovascular medications on critical clinical outcomes such as death and cardiovascular events. Methods A comprehensive search was conducted across four databases, including Medline, Embase, Lilacs, and the Cochrane Library. The review included systematic reviews with meta-analyses that reported risk estimates for adherence to cardiovascular medications. Four systematic reviews, each incorporating observational studies, were selected. Results An increase in adherence to medications significantly reduces the risk of cardiovascular events, stroke, and all-cause death. Specifically, a 20% improvement in adherence to antihypertensive, lipid-lowering, and other cardiovascular medications correlated with reductions in cardiovascular events by 7%, 10%, and 9%, respectively; stroke by 17%, 13%, and 18%; and death by 12%, 9%, and 10%. The certainty of the evidence was moderate, suggesting that these effects are likely present. These findings emphasize the importance of enhancing medication adherence to improve clinical outcomes in CVD management. Conclusions Evidence has demonstrated reductions in hard endpoints in both primary and secondary prevention through the control of conditions such as hypertension and elevated LDL cholesterol concentrations, as well as the benefits of antiplatelet therapy in atherosclerotic disease. However, additional studies are needed to better elucidate the relationship between adherence to cardiovascular medications and the improvement of critical clinical outcomes.


  • Open Access

    Risco de Desfechos Adversos à Saúde em Pacientes com Baixa Adesão ao Tratamento Medicamentoso Cardiovascular: Uma Revisão Sistemática

    by Marcus Vinícius Bolívar Malachias, Sergio Emanuel Kaiser, Denilson Campos de Albuquerque, Andrea Araújo Brandão, Andrei Carvalho Sposito, Lidia Zytysnky Moura, Lucélia Batista Neves Cunha Magalhães, Marco Antonio Mota-Gomes, Nadine Clausell, Paulo César Veiga Jardim, et al.

    Resumo Fundamento As doenças cardiovasculares (DCV) são a principal causa de mortes no mundo. A adesão ao tratamento medicamentoso é um fator importante no manejo de DCV crônicas, influenciando diretamente a ocorrência de desfechos e custos da saúde. Objetivos Esta revisão sistemática, apoiada pela Sociedade Brasileira de Cardiologia, tem como objetivo avaliar o impacto da baixa adesão aos medicamentos para DCV sobre desfechos clínicos críticos como morte e eventos cardiovasculares. Métodos Foi realizada uma busca abrangente em quatro bases de dados: Medline, Embase, Lilacs e Cochrane. Foram incluídas revisões sistemáticas e metanálises que avaliaram estimativas de risco para adesão aos medicamentos cardiovasculares. Quatro revisões sistemáticas, cada uma incorporando estudos observacionais, foram selecionadas. Resultados O aumento na adesão aos medicamentos reduz significativamente o risco de eventos cardiovasculares, acidente vascular cerebral (AVC) e morte por todas as causas. Uma melhoria de 20% na adesão a medicamentos anti-hipertensivos, hipolipemiantes e outros medicamentos cardiovasculares foi correlacionada com reduções nos eventos cardiovasculares em 7%, 10% e 9%, respectivamente; AVC em 17%, 13% e 18%; e morte em 12%, 9% e 10%. A certeza das evidências foi moderada, sugerindo que esses efeitos provavelmente estão presentes. Esses achados enfatizam a necessidade de aumentar a adesão aos tratamentos para melhorar os desfechos clínicos no manejo das DCV. Conclusões Evidências demonstraram reduções em morte e desfechos críticos, tanto na prevenção primária quanto na secundária, por meio do controle de condições como hipertensão e colesterol LDL elevado, assim como benefícios da terapia antiplaquetária na doença aterosclerótica. Mais estudos são necessários para melhor elucidar a relação entre a adesão aos medicamentos cardiovasculares e a melhora de desfechos clínicos críticos.


  • Open Access

    A cost-effectiveness analysis of a novel algorithm to sequentially diagnose leprosy based on manufactured tests under the SUS perspective

    by Milene Rangel da Costa, Carlos Alberto da Silva Magliano, Bruno Monteiro Barros, Quenia Cristina Dias Morais, Andressa Araujo Braga, Kátia Marie Simões e Senna, Ciro Martins Gomes, Alexandre Casimiro de Macedo, Marisa da Silva Santos

    Brazil has the second largest number of leprosy cases (a disease with a significant burden) in the world. Despite global and local efforts to eliminate this public health problem, inadequate or late diagnosis contribute to perpetuate its transmission, especially among household contacts. Tests such as the rapid IgM antibody detection (RT) and real-time polymerase chain reaction (RT-PCR) were developed to overcome the challenges of early diagnosis of leprosy. This study aimed to analyze the cost-effectiveness of a new diagnostic algorithm recommended by the Brazilian government to diagnose leprosy in household contacts of confirmed leprosy cases, which includes the RT and RT-PCR tests. A decision tree model was constructed and the perspective of the Brazilian Unified National Health System (SUS) and a 1-year time horizon were adopted. Only direct medical costs related to diagnostic tests were included. Effectiveness was measured as the number of avoided undiagnosed leprosy cases. Different scenarios were analyzed. The sequential use of RT, slit-skin smear (SSS) microscopy, and RT-PCR as recommended by the Brazilian Ministry of Health was compared to a base case (isolated SSS microscopy), yielding an incremental cost-effectiveness ratio of USD 616.46 per avoided undiagnosed leprosy case. Univariate sensitivity analysis showed that the prevalence of leprosy among household contacts was the variable that influenced the model the most. This is the first economic model to analyze a diagnostic algorithm of leprosy. Results may aid managers to define policies and strategies to eradicate leprosy in Brazil.


  • Open Access

    Availability of Natriuretic Peptide Testing in Primary Public Health Care in Brazil

    by Andressa Araujo Braga, Marisa da Silva Santos, Bernardo Rangel Tura, Bruno Monteiro Barros, Quenia Cristina Dias Morais, Ione Gualandi Oliveira

    Background: Early detection of heart failure makes it possible to intervene in risk factors, and treatment is capable of modifying the natural history of the disease. For diagnostic confirmation, natriuretic peptide (NP) testing or transthoracic echocardiography can be performed; the former is preferable when considering cost and accessibility. Although this test was incorporated into the Brazilian Unified Health System (SUS) in 2018, requests for this test were registered in only 4.63% of municipalities in the SUS Outpatient Information System [...] Abstract Background: Early detection of heart failure makes it possible to intervene in risk factors, and treatment is capable of modifying the natural history of the disease. For diagnostic confirmation, natriuretic peptide (NP) testing or transthoracic echocardiography can be performed; the former is preferable when considering cost and accessibility. Although this test was incorporated into the Brazilian Unified Health System (SUS) in 2018, requests for this test were registered in only 4.63% of municipalities in the SUS Outpatient Information System